Recruiting
Phase 1
Phase 2

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis

Sponsor:

Kyverna Therapeutics

Code:

NCT05938725

Conditions

Lupus Nephritis

Lupus Nephritis - World Health Organization (WHO) Class III

Lupus Nephritis - WHO Class IV

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

KYV-101 anti-CD19 CAR-T cell therapy

Standard lymphodepletion regimen

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information